Cancer vaccines: What do we need to measure in clinical trials?

被引：8
作者：
Kudrin, Alex [1 ]
机构：
[1] Celltrion Inc, Inchon, South Korea
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2014年 / 10卷 / 11期
关键词：
cancer vaccines; endpoints; immune response; patient reported outcomes; progression free survival; SIPULEUCEL-T; IMMUNOTHERAPY; SURVIVAL; APPROVAL; THERAPY;
D O I：
10.4161/hv.27586
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is dedicated to evaluate remaining challenges in capturing clinical response with cancer vaccines. Definition of disease progression in context of clinical rather image-specific criteria and interpretation of efficacy in relation to delayed effect of cancer vaccines should be taken into account in the design of future of immunotherapy trials.
引用
收藏
页码：3236 / 3240
页数：5
相关论文
共 10 条
  • [1] Early Accelerated Approval for Highly Targeted Cancer Drugs
    Chabner, Bruce A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) : 1087 - 1089
  • [2] Substantial Evidence: When Is a Single Trial Sufficient for Approval and Promotion?
    Coutant, David
    Riggs, David
    Hoffman, Elizabeth Van Sant
    [J]. DRUG INFORMATION JOURNAL, 2011, 45 (03): : 253 - 263
  • [3] KIDNEY CANCER Overall survival is an unsuitable primary end point
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    [J]. NATURE REVIEWS UROLOGY, 2010, 7 (07) : 367 - 368
  • [4] ESTIMATING THE OVERALL SURVIVAL BENEFIT OF SIPULEUCEL-T IN THE IMPACT TRIAL ACCOUNTING FOR CROSSOVER TREATMENT IN CONTROL SUBJECTS WITH AUTOLOGOUS IMMUNOTHERAPY GENERATED FROM CYROPRESERVED CELLS
    Gomella, Leonard
    Nabhan, Chadi
    DeVries, Todd
    Whitmore, James
    Frohlich, Mark
    George, Daniel
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04) : E278 - E279
  • [5] A clinical development paradigm for cancer vaccines and related biologics
    Hoos, Axel
    Parmiani, Giorgio
    Hege, Kristen
    Sznol, Mario
    Loibner, Hans
    Eggermont, Alexander
    Urba, Walter
    Blumenstein, Brent
    Sacks, Natalie
    Keilholz, Ulrich
    Nichol, Geoffrey
    [J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (01) : 1 - 15
  • [6] Improved Endpoints for Cancer Immunotherapy Trials
    Hoos, Axel
    Eggermont, Alexander M. M.
    Janetzki, Sylvia
    Hodi, F. Stephen
    Ibrahim, Ramy
    Anderson, Aparna
    Humphrey, Rachel
    Blumenstein, Brent
    Old, Lloyd
    Wolchok, Jedd
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (18): : 1388 - 1397
  • [7] Ovarian Cancer Treatments on the Horizon
    Schmidt, Charlie
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17) : 1284 - 1285
  • [8] The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature
    Sonpavde, Guru
    Di Lorenzo, Giuseppe
    Higano, Celestia S.
    Kantoff, Philip W.
    Madan, Ravi
    Shore, Neal D.
    [J]. EUROPEAN UROLOGY, 2012, 61 (04) : 639 - 647
  • [9] Combining immunotherapy and targeted therapies in cancer treatment
    Vanneman, Matthew
    Dranoff, Glenn
    [J]. NATURE REVIEWS CANCER, 2012, 12 (04) : 237 - 251
  • [10] Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
    Wolchok, Jedd D.
    Hoos, Axel
    O'Day, Steven
    Weber, Jeffrey S.
    Hamid, Omid
    Lebbe, Celeste
    Maio, Michele
    Binder, Michael
    Bohnsack, Oliver
    Nichol, Geoffrey
    Humphrey, Rachel
    Hodi, F. Stephen
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7412 - 7420
1